Soluble CD30, tumour necrosis factor (TNF)-α, and TNF receptors in primary HIV-1 infection: Relationship with HIV-1 RNA, clinical outcome and early antiviral therapy

Journal of Biological Regulators and Homeostatic Agents

Volumn 11, Issue 1-2, 1997, Pages 43-49

  Rizzardi, G P ^a   Tambussi, G ^b   Barcellini, W ^c   Capiluppi, B ^b   Clerici, E ^b   La Maestra, L ^c   Lillo, F ^b   Pantaleo, G ^a   Lazzarin, A ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Antiviral therapy; HIV 1 RNA; Primary HIV 1 infection; Soluble CD30; Soluble TNF receptors; TNF

Indexed keywords

ANTIVIRUS AGENT; CD30 ANTIGEN; CD4 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS RNA;

CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PATIENT CARE; T LYMPHOCYTE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030779592     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Muñoz A, Wang MC, Bass S, et al. Acquired immunodeficiency syndrome (AIDS)-free time after human immunodeficiency virus type 1 (HIV-1) seroconversion in homosexual men. Multicenter AIDS Cohort Study Group. Am J Eipidemiol 1989; 130: 530-9
2. Enger C, Graham N, Peng Y, et al. Survival from early, intermediate, and late stages of HIV infection. JAMA 1996; 275: 1329-34.
3. Muñoz A, Kirby AJ, He YD, et al. Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. J AIDS Hum Retrovirol 1995;8:496-505.
4. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996; 271: 324-8.
5. Lifson AR, Buchbinder SP, Sheppard HW, et al. Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics. J Infect Dis 1991; 163: 959-65.
6. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. AIDS 1994; 8: 1123-8.
7. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993; 7: 1159-66.
8. Levy JA. HIV pathogenesis and long-term survival. AIDS 1993; 7: 1401-10.
9. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995; 332: 228-32.
10. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologie and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332: 201-8.
11. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 209-16.
12. Tsoukas CM, Bernard NF. Markers predicting progression of human immunodeficiency virus-related disease. Clin Microbiol Rev 1994, 7: 14-28.
13. Mellors JW, Kingsley LA, Rinaldo CJ, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-9.
14. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-70.
15. Hirsch VM, Fuerst TR, Sutter G, et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 1996; 70: 3741-52.
16. Jurriaans S, van Gemen B, Weverling GJ, et al. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 1994; 204: 223-33.
17. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-54.
18. Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997; 126: 929-38.
19. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med 1997; 126: 939-45.
20. Pantalco G, Fauci AS. Immunopathogenesis of HIV infection. Ann Rev Microbiol 1996; 50: 825-54.
21. Pantaleo G, Graziosi C, Fauci AS. Virologic and immunologic events in primary HIV infection. Springer Sem Immunopath 1997; 18: 257-66.
22. Pantaleo G, Fauci AS. Introduction: recent advances in the pathogenesis of human immunodeficiency virus infection. Springer Sem Immunopath 1997; 18: 253-6.
23. Pantaleo G, Demarest JF, Schacker T, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. PNAS 1997, 94: 254-8.
24. Rizzardi GP, Barcellini W, Tambussi G, et al. Plasma levels of soluble CD30, tumour necrosis factor (TNF)-α and TNF receptors during primary HIV-1 infection. Correlation with HIV-1 RNA and the clinical outcome. AIDS 1996; 10: F45-F50.
25. Barcellini W, Rizzardi GP, Poli G, et al. Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. AIDS Res Human Retrov 1996; 12: 325-31.
26. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults MMWR 1992; 41: 1-19.
27. Kinloch-de Loës S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. New Engl J Med 1995; 333: 408-13.
28. Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection Ann Intern Med 1996; 124: 654-63.
29. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996; 384: 529-34.
30. Pantaleo G, Cohen OJ, Schwartzentruber DJ, Graziosi C, Vaccarezza M, Fauci AS. Pathogenic insights from studies of lymphoid-tissue from HIV-infected individuals. J AIDS 1995; 10: S6-S14.
31. Pantaleo G, Demarest JF, Soudeyns H, et al. Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV. Nature 1994; 370: 463-7.
32. Graziosi C, Pantaleo G, Butini L, et al. Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. PNAS 1993; 90: 6405-9.
33. Graziosi C, Pantaleo G New concepts in the immunopathogenesis of HIV infection. J Biol Reg Homeos Ag 1995; 9: 73-5.
34. Graziosi C, Gantt KR, Vaccarezza M, et al. Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection PNAS 1996; 93: 4386-91.
35. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-6
36. Ho D. Viral counts count in HIV infection. Science 1996; 272: 1124-5.
37. Wei X, Ghosh SK. Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22.